The long terminal repeat sequences of a novel human endogenous retrovirus

Science ◽  
1984 ◽  
Vol 226 (4679) ◽  
pp. 1204-1206 ◽  
Author(s):  
C. O'Connell ◽  
M Cohen
Keyword(s):  
Long Terminal Repeat ◽  
Endogenous Retrovirus ◽  
Terminal Repeat ◽  
Human Endogenous Retrovirus ◽  
Repeat Sequences

scholarly journals The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis

Oncotarget ◽  
2018 ◽  
Vol 9 (31) ◽  
pp. 22069-22078 ◽  
Author(s):  
Masataka Shimonosono ◽  
Takaaki Arigami ◽  
Shigehiro Yanagita ◽  
Daisuke Matsushita ◽  
Yasuto Uchikado ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Long Terminal Repeat ◽  
Endogenous Retrovirus ◽  
Terminal Repeat ◽  
Cancer Prognosis ◽  
Human Endogenous Retrovirus

scholarly journals A Novel Function of RNAs Arising From the Long Terminal Repeat of Human Endogenous Retrovirus 9 in Cell Cycle Arrest

2012 ◽  
Vol 87 (1) ◽  
pp. 25-36 ◽  
Author(s):  
L. Xu ◽  
A. G. Elkahloun ◽  
F. Candotti ◽  
A. Grajkowski ◽  
S. L. Beaucage ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Long Terminal Repeat ◽  
Cell Cycle Arrest ◽  
Endogenous Retrovirus ◽  
Terminal Repeat ◽  
Human Endogenous Retrovirus ◽  
Cycle Arrest

scholarly journals The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Yao Xiao ◽  
Hao Li ◽  
Lei-Lei Yang ◽  
Liang Mao ◽  
Cong-Cong Wu ◽  
...  
Keyword(s):  
T Cell ◽  
Long Terminal Repeat ◽  
Immune Checkpoint ◽  
Expression Patterns ◽  
Endogenous Retrovirus ◽  
Terminal Repeat ◽  
Human Endogenous Retrovirus ◽  
Expression Levels ◽  
Immune Checkpoint Molecules ◽  
Immunoglobulin Domain

Human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) and transmembrane and immunoglobulin domain containing 2 (TMIGD2) are new immune checkpoint molecules of the B7:CD28 family; however, little research has been performed on these immune checkpoint molecules. In this study, we used oral squamous cells carcinoma (OSCC) tissue microarrays and immunohistochemistry methods to investigate the expression patterns of HHLA2 and TMIGD2 in OSCC. After comparing the HHLA2 and TMIGD2 expression levels in OSCC, dysplasia, and mucosa, we found increased HHLA2 expression in OSCC and dysplasia, while the TMIGD2 expression was decreased in OSCC and dysplasia. Using the Kaplan-Meier method and log-rank test, we found that higher HHLA2 or TMIGD2 expression levels in OSCC indicate poor prognosis. Furthermore, two-tailed Pearson’s statistical analysis revealed that the HHLA2 expression levels in OSCC, dysplasia, and mucosa were positively correlated with the T cell immunoglobulin and mucin-domain containing-3 (TIM3), lymphocyte-activation gene 3 (LAG3), B7 homolog 3 protein (B7-H3), B7 homolog 4 protein (B7H4), and V-domain Ig suppressor of T cell activation (VISTA) levels, while the TMIGD2 expression levels in OSCC, dysplasia, and mucosa were inversely correlated with the TIM3, LAG3, and B7H3 levels. Our current study demonstrates that HHLA2 may serve as an immune target for OSCC therapy and that the TMIGD2 expression level in OSCC could forecast patient prognosis.

Sign in / Sign up

Export Citation Format

Share Document